Arginine supplementation in prevention of necrotizing enterocolitis in the premature infant: an updated systematic review
Open Access
- 10 September 2014
- journal article
- research article
- Published by Springer Nature in BMC Pediatrics
- Vol. 14 (1) , 1-10
Abstract
Hypoxic-ischemic injury is thought to play a significant role in necrotizing enterocolitis (NEC). Nitric Oxide (NO) is the principal inhibitory neurotransmitter in the gut and is involved in regulation of mucosal blood flow and maintenance of mucosal integrity. NO is synthesized from L-arginine by NO synthases. Our primary objective was to determine the effectiveness of supplemental L-arginine versus placebo in prevention of NEC in preterm infants ≤ 34 weeks gestational age by systematic review of published randomized controlled trials (RCTs). This review included RCTs in which L-arginine was administered as a supplement to neonates to prevent NEC. Searches were conducted in OVID MEDLINE, EMBASE, PubMed, and CINAHL from their dates of inception to July, 2014. Inclusion criteria were informed parental consent, neonates born at ≤ 34 weeks gestation, and birth weight ≤ 1500 g. Exclusion criteria included neonates with severe congenital anomalies and inborn errors of metabolism. Incidence of NEC was the primary outcome measure. Whole data were analyzed by RevMan 5.1 (Update Software, Oxford, UK). Outcome data were analyzed to determine risk ratios, number needed to treat, confidence intervals, and test for overall effect. Two trials including 425 neonates were eligible for this review. Of these, 235 neonates were included in the study. L-arginine had a 59% reduction in the incidence of stage II and III NEC (RR 0.41, 95% CI 0.20 to 0.85, NNT = 9) compared with placebo (P = 0.02). A similar finding was identified for all stages of NEC (60% reduction, RR 0.40, 95% CI 0.23 to 0.69, NNT = 5) (P = 0.001). At age 3 yrs, there was no significant difference between the 2 groups in terms of any neurodevelopmental disability (RR 0.65; 95% CI 0.23-1.83, P = 0.41). L-arginine supplementation appears to be protective in prevention of NEC in preterm infants and without any significant impact on neurodevelopmental outcomes at 36 months of corrected age. With the addition of the results of one more study to the literature, an intriguing role for L-arginine supplementation continues to gain support. However, large multi-centre RCTs are needed before this can become common practice.Keywords
This publication has 36 references indexed in Scilit:
- Enteral L‐Arginine Supplementation for Prevention of Necrotizing Enterocolitis in Very Low Birth Weight NeonatesJournal of Parenteral and Enteral Nutrition, 2013
- Neurodevelopmental outcomes of premature infants treated with l‐arginine for prevention of necrotising enterocolitisJournal of Paediatrics and Child Health, 2009
- The Role of Nitric Oxide in Intestinal Epithelial Injury and Restitution in Neonatal Necrotizing EnterocolitisSeminars in Perinatology, 2008
- Arginine supplementation for prevention of necrotising enterocolitis in preterm infants2007
- Endothelin-1 in Human Intestine Resected for Necrotizing EnterocolitisThe Journal of Pediatrics, 2005
- Neonatal Necrotizing Enterocolitis: Clinical Considerations and Pathogenetic ConceptsPediatric and Developmental Pathology, 2003
- The role of inflammatory cytokines and nitric oxide in the pathogenesis of necrotizing enterocolitisJournal of Pediatric Surgery, 1997
- Models of the pathogenesis of necrotizing enterocolitisThe Journal of Pediatrics, 1990
- Superoxide: A critical oxygen-free radical in ischemic bowel injuryJournal of Pediatric Surgery, 1984
- Gastrointestinal permeability changes in the preterm neonate.Archives of Disease in Childhood, 1982